GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Medicenna Therapeutics Corp (TSX:MDNA) » Definitions » EBITDA Margin %

Medicenna Therapeutics (TSX:MDNA) EBITDA Margin % : 0.00% (As of Dec. 2023)


View and export this data going back to 2015. Start your Free Trial

What is Medicenna Therapeutics EBITDA Margin %?

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Medicenna Therapeutics's EBITDA for the three months ended in Dec. 2023 was C$-4.78 Mil. Medicenna Therapeutics's Revenue for the three months ended in Dec. 2023 was C$0.00 Mil. Therefore, Medicenna Therapeutics's EBITDA margin for the quarter that ended in Dec. 2023 was 0.00%.


Medicenna Therapeutics EBITDA Margin % Historical Data

The historical data trend for Medicenna Therapeutics's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Medicenna Therapeutics EBITDA Margin % Chart

Medicenna Therapeutics Annual Data
Trend Dec15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
EBITDA Margin %
Get a 7-Day Free Trial Premium Member Only - - - - -

Medicenna Therapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Medicenna Therapeutics's EBITDA Margin %

For the Biotechnology subindustry, Medicenna Therapeutics's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Medicenna Therapeutics's EBITDA Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Medicenna Therapeutics's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Medicenna Therapeutics's EBITDA Margin % falls into.



Medicenna Therapeutics EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Medicenna Therapeutics's EBITDA Margin % for the fiscal year that ended in Mar. 2023 is calculated as

EBITDA Margin %=EBITDA (A: Mar. 2023 )/Revenue (A: Mar. 2023 )
=-16.298/0
= %

Medicenna Therapeutics's EBITDA Margin % for the quarter that ended in Dec. 2023 is calculated as

EBITDA Margin %=EBITDA (Q: Dec. 2023 )/Revenue (Q: Dec. 2023 )
=-4.775/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Medicenna Therapeutics  (TSX:MDNA) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.


Medicenna Therapeutics EBITDA Margin % Related Terms

Thank you for viewing the detailed overview of Medicenna Therapeutics's EBITDA Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Medicenna Therapeutics (TSX:MDNA) Business Description

Traded in Other Exchanges
Address
2 Bloor Street W., 7th Floor, Toronto, ON, CAN, M4W 3E2
Medicenna Therapeutics Corp is a Canada-based immuno-oncology company. Its principal business activity is the development and commercialization of IL-2, IL-4, and IL13 Superkines and Empowered Superkines for the treatment of cancer and other diseases. Its pipeline candidates include MDNA55 for recurrent glioblastoma multiforme (rGBM), MDNA11 for Cancer immunotherapies, MDNA209 for Autoimmune Diseases, MDNA413 for Cancer immunotherapies, and MDNA132 for Solid Tumors, BiSKITs represents the novel platform comprised of Bifunctional SuperKine ImmunoTherapies.
Executives
Albert George Beraldo Director
Chandra Panchal Director

Medicenna Therapeutics (TSX:MDNA) Headlines

No Headlines